Having trouble accessing articles? Reset your cache.

PHIP the script

How one new target could treat three tough cancers lacking common mutations

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types.

A group led by researchers at California Pacific Medical Center Research

Read the full 436 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers